Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis

Detalhes bibliográficos
Autor(a) principal: Fragoso,Yara Dadalti
Data de Publicação: 2016
Outros Autores: Alves-Leon,Soniza Vieira, Becker,Jefferson, Brooks,Joseph Bruno Bidin, Correa,Eber Castro, Damasceno,Alfredo, Gama,Paulo Diniz da, Gama,Rodrigo Assad da, Matta,Andre Palma da Cunha, Maciel,Ernane Pires, Winckler,Thereza Cristina d’Avila
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos de neuro-psiquiatria (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2016000800650
Resumo: ABSTRACT Objective To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results After a median period of nine months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events were reported. Conclusion Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on multiple sclerosis management, however, is essential for drug switching.
id ABNEURO-1_0b41607b32769f71f2e57870a7273df6
oai_identifier_str oai:scielo:S0004-282X2016000800650
network_acronym_str ABNEURO-1
network_name_str Arquivos de neuro-psiquiatria (Online)
repository_id_str
spelling Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosismultiple sclerosisnatalizumabfingolimod hydrochloridetherapeuticsABSTRACT Objective To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results After a median period of nine months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events were reported. Conclusion Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on multiple sclerosis management, however, is essential for drug switching.Academia Brasileira de Neurologia - ABNEURO2016-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2016000800650Arquivos de Neuro-Psiquiatria v.74 n.8 2016reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/0004-282X20160090info:eu-repo/semantics/openAccessFragoso,Yara DadaltiAlves-Leon,Soniza VieiraBecker,JeffersonBrooks,Joseph Bruno BidinCorrea,Eber CastroDamasceno,AlfredoGama,Paulo Diniz daGama,Rodrigo Assad daMatta,Andre Palma da CunhaMaciel,Ernane PiresWinckler,Thereza Cristina d’Avilaeng2016-08-19T00:00:00Zoai:scielo:S0004-282X2016000800650Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2016-08-19T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse
dc.title.none.fl_str_mv Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
title Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
spellingShingle Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
Fragoso,Yara Dadalti
multiple sclerosis
natalizumab
fingolimod hydrochloride
therapeutics
title_short Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
title_full Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
title_fullStr Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
title_full_unstemmed Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
title_sort Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
author Fragoso,Yara Dadalti
author_facet Fragoso,Yara Dadalti
Alves-Leon,Soniza Vieira
Becker,Jefferson
Brooks,Joseph Bruno Bidin
Correa,Eber Castro
Damasceno,Alfredo
Gama,Paulo Diniz da
Gama,Rodrigo Assad da
Matta,Andre Palma da Cunha
Maciel,Ernane Pires
Winckler,Thereza Cristina d’Avila
author_role author
author2 Alves-Leon,Soniza Vieira
Becker,Jefferson
Brooks,Joseph Bruno Bidin
Correa,Eber Castro
Damasceno,Alfredo
Gama,Paulo Diniz da
Gama,Rodrigo Assad da
Matta,Andre Palma da Cunha
Maciel,Ernane Pires
Winckler,Thereza Cristina d’Avila
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Fragoso,Yara Dadalti
Alves-Leon,Soniza Vieira
Becker,Jefferson
Brooks,Joseph Bruno Bidin
Correa,Eber Castro
Damasceno,Alfredo
Gama,Paulo Diniz da
Gama,Rodrigo Assad da
Matta,Andre Palma da Cunha
Maciel,Ernane Pires
Winckler,Thereza Cristina d’Avila
dc.subject.por.fl_str_mv multiple sclerosis
natalizumab
fingolimod hydrochloride
therapeutics
topic multiple sclerosis
natalizumab
fingolimod hydrochloride
therapeutics
description ABSTRACT Objective To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results After a median period of nine months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events were reported. Conclusion Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on multiple sclerosis management, however, is essential for drug switching.
publishDate 2016
dc.date.none.fl_str_mv 2016-08-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2016000800650
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2016000800650
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/0004-282X20160090
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
dc.source.none.fl_str_mv Arquivos de Neuro-Psiquiatria v.74 n.8 2016
reponame:Arquivos de neuro-psiquiatria (Online)
instname:Academia Brasileira de Neurologia
instacron:ABNEURO
instname_str Academia Brasileira de Neurologia
instacron_str ABNEURO
institution ABNEURO
reponame_str Arquivos de neuro-psiquiatria (Online)
collection Arquivos de neuro-psiquiatria (Online)
repository.name.fl_str_mv Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia
repository.mail.fl_str_mv ||revista.arquivos@abneuro.org
_version_ 1754212780829835264

Registros relacionados